Xenon Pharmaceuticals Inc (XENE)
41.47
+1.67
(+4.20%)
USD |
NASDAQ |
Nov 22, 12:56
Xenon Pharmaceuticals Enterprise Value: 2.380B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 2.380B |
| November 20, 2024 | 2.345B |
| November 19, 2024 | 2.308B |
| November 18, 2024 | 2.267B |
| November 15, 2024 | 2.383B |
| November 14, 2024 | 2.529B |
| November 13, 2024 | 2.546B |
| November 12, 2024 | 2.654B |
| November 11, 2024 | 2.706B |
| November 08, 2024 | 2.777B |
| November 07, 2024 | 2.833B |
| November 06, 2024 | 2.772B |
| November 05, 2024 | 2.630B |
| November 04, 2024 | 2.507B |
| November 01, 2024 | 2.506B |
| October 31, 2024 | 2.462B |
| October 30, 2024 | 2.521B |
| October 29, 2024 | 2.513B |
| October 28, 2024 | 2.510B |
| October 25, 2024 | 2.509B |
| October 24, 2024 | 2.518B |
| October 23, 2024 | 2.504B |
| October 22, 2024 | 2.585B |
| October 21, 2024 | 2.697B |
| October 18, 2024 | 2.746B |
| Date | Value |
|---|---|
| October 17, 2024 | 2.629B |
| October 16, 2024 | 2.576B |
| October 15, 2024 | 2.432B |
| October 14, 2024 | 2.511B |
| October 11, 2024 | 2.469B |
| October 10, 2024 | 2.409B |
| October 09, 2024 | 2.334B |
| October 08, 2024 | 2.455B |
| October 07, 2024 | 2.422B |
| October 04, 2024 | 2.433B |
| October 03, 2024 | 2.355B |
| October 02, 2024 | 2.441B |
| October 01, 2024 | 2.407B |
| September 30, 2024 | 2.330B |
| September 27, 2024 | 2.207B |
| September 26, 2024 | 2.188B |
| September 25, 2024 | 2.162B |
| September 24, 2024 | 2.228B |
| September 23, 2024 | 2.283B |
| September 20, 2024 | 2.320B |
| September 19, 2024 | 2.369B |
| September 18, 2024 | 2.316B |
| September 17, 2024 | 2.316B |
| September 16, 2024 | 2.308B |
| September 13, 2024 | 2.373B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
148.91M
Minimum
Oct 28 2020
3.133B
Maximum
Feb 09 2024
1.271B
Average
1.284B
Median
Enterprise Value Benchmarks
| Aurinia Pharmaceuticals Inc | 906.94M |
| Edesa Biotech Inc | 4.811M |
| Lexaria Bioscience Corp | 25.27M |
| ESSA Pharma Inc | -52.60M |
| ImmunoPrecise Antibodies Ltd | 8.777M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -62.79M |
| Total Expenses (Quarterly) | 73.68M |
| EPS Diluted (Quarterly) | -0.81 |
| Earnings Yield | -6.80% |
| Normalized Earnings Yield | -4.386 |